Skip to Content

Dacomitinib Approval Status

FDA Approved: No (Pending Approval)
Generic name: dacomitinib
Company: Pfizer Inc.
Treatment for: Non-Small Cell Lung Cancer

Dacomitinib is an investigational, oral, once-daily, irreversible pan-human epidermal growth factor receptor tyrosine kinase inhibitor (TKI) in development for the treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations.

Development Status and FDA Approval Process for dacomitinib

DateArticle
Jun  4, 2018Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations
Apr  4, 2018 U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide